Search Results - "Ashe, Karen M."

  • Showing 1 - 18 results of 18
Refine Results
  1. 1

    Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease by Marshall, John, Ashe, Karen M, Bangari, Dinesh, McEachern, KerryAnne, Chuang, Wei-Lien, Pacheco, Joshua, Copeland, Diane P, Desnick, Robert J, Shayman, James A, Scheule, Ronald K, Cheng, Seng H

    Published in PloS one (24-11-2010)
    “…Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency in the activity of the lysosomal hydrolase α-galactosidase A (α-gal)…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Food Insecurity and Obesity: Exploring the Role of Social Support by Ashe, Karen M, Lapane, Kate L

    “…Women are disproportionately affected by both obesity and food insecurity. Food insecurity occurs when there is limited ability to acquire adequate foods. It…”
    Get more information
    Journal Article
  5. 5

    Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease by Ashe, Karen M, Budman, Eva, Bangari, Dinesh S, Siegel, Craig S, Nietupski, Jennifer B, Wang, Bing, Desnick, Robert J, Scheule, Ronald K, Leonard, John P, Cheng, Seng H, Marshall, John

    Published in Molecular medicine (Cambridge, Mass.) (30-04-2015)
    “…Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient activity of α-galactosidase A (α-Gal A). This results in the…”
    Get full text
    Journal Article
  6. 6

    Exposure to Weight Management Counseling Among Students at 8 U.S. Medical Schools by Ashe, Karen M., Geller, Alan C., Pendharkar, Jyothi A., Pbert, Lori, Crawford, Sybil, Clark, Melissa A., Frisard, Christine F., Eno, Cassie A., Faro, Jamie, Ockene, Judith K.

    Published in American journal of preventive medicine (01-05-2021)
    “…Clinical guidelines support physician intervention consistent with the Ask, Advise, Assess, Assist, Arrange framework for adults who have obesity. However,…”
    Get full text
    Journal Article
  7. 7

    α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease by Bangari, Dinesh S, Ashe, Karen M, Desnick, Robert J, Maloney, Colleen, Lydon, John, Piepenhagen, Peter, Budman, Eva, Leonard, John P, Cheng, Seng H, Marshall, John, Thurberg, Beth L

    Published in The American journal of pathology (01-03-2015)
    “…Fabry disease is an X-linked lysosomal storage disease caused by deficient activity of α-galactosidase A and the resultant systemic accumulation of…”
    Get full text
    Journal Article
  8. 8

    Students’ Report of Preceptor Weight Management Counseling at Eight U.S. Medical Schools by Geller, Alan C., Ockene, Judith K., Kulkarni, Mukti, Churchill, Linda C., Frisard, Christine F., Okuliar, Catherine A., Ashe, Karen M., Crawford, Sybil L., Shaw, M. Ann, White, Katherine M., Pbert, Lori A.

    Published in American journal of preventive medicine (01-11-2018)
    “…Primary care providers, using brief counseling, can help patients increase motivation to initiate or maintain weight loss, improve diet, and increase physical…”
    Get full text
    Journal Article
  9. 9

    Systemic Administration of AAV8-α-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic Expression by Nietupski, Jennifer B, Hurlbut, Gregory D, Ziegler, Robin J, Chu, Qiuming, Hodges, Bradley L, Ashe, Karen M, Bree, Mark, Cheng, Seng H, Gregory, Richard J, Marshall, John, Scheule, Ronald K

    Published in Molecular therapy (01-11-2011)
    “…In mice, liver-restricted expression of lysosomal enzymes from adeno-associated viral serotype 8 (AAV8) vectors results in reduced antibodies to the expressed…”
    Get full text
    Journal Article
  10. 10

    Merits of Combination Cortical, Subcortical, and Cerebellar Injections for the Treatment of Niemann-Pick Disease Type A by Bu, Jie, Ashe, Karen M, Bringas, John, Marshall, John, Dodge, James C, Cabrera-Salazar, Mario A, Forsayeth, John, Schuchman, Edward H, Bankiewicz, Krystof S, Cheng, Seng H, Shihabuddin, Lamya S., Passini, Marco A

    Published in Molecular therapy (01-10-2012)
    “…Niemann-Pick disease Type A (NPA) is a neuronopathic lysosomal storage disease (LSD) caused by the loss of acid sphingomyelinase (ASM). The goals of the…”
    Get full text
    Journal Article
  11. 11
  12. 12

    α-Galactosidase A Knockout Mice by Bangari, Dinesh S, Ashe, Karen M, Desnick, Robert J, Maloney, Colleen, Lydon, John, Piepenhagen, Peter, Budman, Eva, Leonard, John P, Cheng, Seng H, Marshall, John, Thurberg, Beth L

    Published in The American journal of pathology (01-03-2015)
    “…Fabry disease is an X-linked lysosomal storage disease caused by deficient activity of α-galactosidase A and the resultant systemic accumulation of…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain by Ashe, Karen M, Chiu, Wan-Ling, Khalifa, Ahmed M, Nicolas, Antoine N, Brown, Bonnie L, De Martino, Randall R, Alexander, Clayton P, Waggener, Christopher T, Fischer-Stenger, Krista, Stewart, Jennifer K

    Published in Neuro-endocrinology letters (2011)
    “…Vesicular monoamine transporter 1 (VMAT-1) mRNA and protein were examined (1) to determine whether adult mouse brain expresses full-length VMAT-1 mRNA that can…”
    Get more information
    Journal Article
  15. 15

    217. Comparison of Hepatic Vein and Peripheral Vein Delivery of an AAV2/8 Vector Encoding Human a-Galactosidase A to Rhesus Macaques by Hodges, Bradley L., Chu, Qiuming, Nietupski, Jennifer B., Ashe, Karen M., Taylor, Kristin M., Ziegler, Robin J., Cheng, Seng H., Marshall, John, Scheule, Ronald K.

    Published in Molecular therapy (01-05-2006)
    “…In murine models of lysosomal storage diseases, sustained hepatocyte-restricted expression and secretion of the therapeutic enzyme is capable of correcting the…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Merits of Combination Cortical, Subcortical, and Cerebellar Injections for the Treatment of Niemann-Pick Disease Type A by Bu, Jie, Ashe, Karen M, Bringas, John, Marshall, John, Dodge, James C, Cabrera-Salazar, Mario A, sayeth, John, Schuchman, Edward H, Bankiewicz, Krystof S, Cheng, Seng H, Shihabuddin, Lamya S, Passini, Marco A

    Published in Molecular therapy (01-10-2012)
    “…Niemann-Pick disease Type A (NPA) is a neuronopathic lysosomal storage disease (LSD) caused by the loss of acid sphingomyelinase (ASM). The goals of the…”
    Get full text
    Journal Article
  18. 18

    Systemic Administration of AAV8-[alpha]-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic Expression by Nietupski, Jennifer B, Hurlbut, Gregory D, Ziegler, Robin J, Chu, Qiuming, Hodges, Bradley L, Ashe, Karen M, Bree, Mark, Cheng, Seng H, Gregory, Richard J, Marshall, John, Scheule, Ronald K

    Published in Molecular therapy (01-11-2011)
    “…In mice, liver-restricted expression of lysosomal enzymes from adeno-associated viral serotype 8 (AAV8) vectors results in reduced antibodies to the expressed…”
    Get full text
    Journal Article